January 9, 2018 by Dan Leonard and Chain Drug Review
biopharma discoveries, biotech innovation, business of health care, Dan Leonard, National Pharmaceutical Council, NPC, precision medicines
Opinion
Today we’re seeing significant scientific breakthroughs that are revolutionizing the treatment of challenging conditions like cancers and both rare and chronic diseases. Advances that activate the immune system or retool genes with a single treatment to change the course of disease all signal that personalized medicine is here and continuing to evolve. These amazing and
August 8, 2017 by Dan Leonard and Chain Drug Review
Dan Leonard, formulary medications, formulary tiers, National Pharmaceutical Council, specialty medicines, tiered formularies
Opinion
Suppose two customers who are both diagnosed with rheumatoid arthritis approach your pharmacy counter. The first line of treatment for rheumatoid arthritis works effectively for the first customer, but it doesn’t work well in managing the second customer’s symptoms. The second customer’s doctor recommends another treatment that is more effective for her, yet it is
April 23, 2017 by Dan Leonard and Chain Drug Review
Dan Leonard, HDHPs, health savings account, high-deductible health plans, HSA, National Pharmaceutical Council, pharmacy benefits
2017, Issue 04-24-2017, Issues, Leading Headlines, Opinion
Imagine you are a 40-year-old woman who is one of the 1.5 million people in the U.S. with rheumatoid arthritis (RA), a chronic condition for which you take regular medication to control flares of the disease, stiffness and pain. But before you get to the pharmacy counter, early in the year you receive a painful
January 4, 2017 by Dan Leonard and Chain Drug Review
biopharmaceutical research, Dan Leonard, evidence-based medical decision making, medication nonadherence, National Pharmaceutical Council, NPC, pharmaceutical spending, value-based health care
Opinion
For the past two years, organizations in the private and public sectors have been working to develop tools to support value-based health care and evidence-based medical decision making. In 2017, these efforts will take on an even greater urgency, driven by the ongoing, accelerating progress of biopharmaceutical research and development. As more — and more
April 27, 2016 by Dan Leonard and Chain Drug Review
Dan Leonard, health care costs, National Pharmaceutical Council, value-based insurance design
Opinion
With the heated rhetoric about Obamacare on the presidential campaign trail, congressional hearings focused on drug costs and news reports about these debates, is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and appropriate treatments and encourage future innovation? We believe
August 10, 2015 by Dan Leonard and Chain Drug Review
Affordable Care Act, Dan Leonard, high-deductible health plans, medication adherence, medication therapy management, National Pharmaceutical Council, tiered formularies, value-based insurance design
2015, Issue 08-10-2015, Issues, Opinion
If the lack of medication adherence were an easy problem to solve, then everyone would be taking their medicines as directed, there would be no need for iPhone apps or electronic pill bottle reminders, patient health outcomes would be improved, and overall health care costs would be lower because of reduced complications or hospitalizations. Yet
May 1, 2015 by Dan Leonard and Chain Drug Review
accountable care organizations, ACOs, Dan Leonard, National Pharmaceutical Council, Sylvia Burwell, value-based care
Opinion, Pharmacy
Recently, U.S. Health and Human Services (HHS) Secretary Sylvia Burwell announced a lofty goal of tying 50% of all traditional Medicare payments to alternative payment models, such as accountable care organizations (ACOs) or bundled payment arrangements, by the year 2018. In announcing these ambitious goals, Burwell stated, “Whether you are a patient, a provider, a